Over the years, we have continued to cover the UBS Quality Growth at a Reasonable Price (Q-GARP) portfolio, and with good reason. The portfolio managers have always focused on high-quality U.S. growth companies that they believe are trading at attractive valuations. They continue searching for these top stocks, and they maintain that the recent volatility in the market has had no impact on their process.
The Q-GARP portfolio has consistently outperformed the S&P 500 since inception in 2007, and it offers investors an outstanding portfolio using an initial quantitative screen of stocks based on:
- Quality metrics: high and stable profitability
- Growth: high expected earnings growth
- Valuation: low valuation relative to peers
The final list is a compilation of quality growth stocks that it believes are trading at attractive valuations.
Recently the managers removed AmerisourceBergen Corp (NYSE: ABC) and used the proceeds from the sale to increase the position they already held in Unitedhealth Group Inc. (NYSE: UNH).
These three other top health care stocks also are in the Q-GARP portfolio.
This top life sciences company is a favorite across Wall Street. Danaher Corp. (NYSE: DHR) is now one of the largest and most diversified life sciences companies. Its products include analytical instruments and consumables for life sciences research, diagnostics, dental instruments and consumables, as well as equipment and services used in water quality testing and product identification.
The company is known as having leading brands across many verticals, with a strong management team and a record of superior execution. UBS sees core growth continuing to accelerate via acquisitions, noting that the company is focused on growth markets with recurring revenue streams and high gross margins.
Shareholders receive just a 0.65% dividend. The UBS price target on the shares is $115, while the Wall Street consensus target is $111.44. The shares traded at $102.25 early Monday.
This company is based in Ireland after the gigantic combination with Covidien three years ago. Medtronic PLC (NYSE: MDT) is a medical devices giant, and many on Wall Street saw its historical merger with Covidien, probably one of the largest in the med tech industry, as a momentous event, leading to the creation of a unique company that combines the extensive and innovative abilities of both companies. The combined company officially has joint forces of over 85,000 employees in more than 160 countries.
Top analysts feel that the contributions from Medtronic’s three growth drivers, which they cite as therapy innovation, globalization and services/solutions, should support a 5% or greater constant currency top-line growth this year and beyond.
Medtronic investors are paid a 2.15% dividend. The consensus price target was last seen at $91.37. Shares were last seen trading at $85.40.
Thermo Fisher Scientific
This is another top health care play for investors looking to be in the sector but without drug pricing worries. Thermo Fisher Scientific Inc. (NYSE: TMO) is the largest and most diversified life sciences company. It offers a comprehensive product portfolio consisting of analytical instrumentation, lab equipment, consumables, software and services used for throughout research, drug manufacturing, diagnostics, food and consumer product safety, and environmental testing.
Thermo Fisher Scientific helps customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through the company’s premier brands — Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services — it offers an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.
Investors are paid a tiny 0.31% dividend. The posted consensus price target is $245.47. The stock traded at $216.40.
The Q-GARP portfolio managers feel these top stocks hit the firm’s criteria for solid growth potential at a price that is not stretched. In a market where most valuations are, these all make good sense for the rest of 2018.